World Biosimilars (Follow-on biologics) Industry Overview

• Publication date: November 2010

The biosimilars industry is sector ed into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest industry sector since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications. Overburdened due to rising heal...

The biosimilars industry is sector ed into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest industry sector since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications.

Overburdened due to rising healthcare costs, ageing population, expensive drugs and pharmaceutical expenditure, biosimilar industry is getting boost from increasing user acceptance and emerging Indian and Chinese industry s. The major challenge for the biosimilar industry is risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar industry is immense, as biologics are going to be off patent by 2015 and an anticipated approval pathway in U.S will open up potentially largest industry . The growth potential of the biosimilars industry is expected to be strong, with patents for a number of second-generation therapeutic proteins (Enbrel, Remicade, Herceptin, etc.) slated for expiry between 2013 and 2019. The global biosimilars industry is highly fragmented with the presence of some leading players such as Biocon, Dr Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt.

The report titled “” covers the overview, industry size and sector ation of the biosimilars industry . The various drivers and the challenges faced by the industry are also discussed in detail. The competitive aspect of the industry is also highlighted and the key players are profiled with their strategies for this industry .

Global Biotechnology Industry

I. Global Biopharmaceutical Industry

II. Global Biosimilars Industry

II. 1 Overview
II. 2 Industry Value
II. 3 Geographical Segmentation
II. 4 Currently Industry ed Biosimilars
II. IV. 1 Erythropoietin
II. IV. 2 Human Growth Hormone
II. IV. 3 Filgrastim

III. Industry Drivers

III. 1 Rising Healthcare Costs
III. 2 Large Number of Blockbuster Biologics Slated for Patent Expiry
III. 3 Leading Generics Players Spearheading Development
III. 4 Rise in Ageing Population
III. 5 Cost Effective Option for Pharmaceutical Firms

IV. Industry Constraints

IV. 1 Regulatory Restrictions and Hurdles
IV. 2 High Development Costs 24
IV. 3 Manufacturing Complexities

V. Opportunities

V. 1 Burgeoning Indian and Chinese Industry
V. 2 Monoclonal Antibodies- Fastest Growing sector

VI. Industry Outlook

VII. Major Players

VII. 1 Teva Pharmaceuticals Market Ltd.
VII. I. 1 Business Description
VII. I. 2 Corporate Strategy

VII. 2 Biocon
VII. II. 1 Business Description
VII. II. 2 Corporate Strategy

VII. 3 Hospira Inc.
VII. III. 1 Business Description
VII. III. 2 Corporate Strategy

Charts and Figures

Biopharmaceutical Value Chain
Global Biopharmaceutical Industry (2004-2009)
Global Biopharmaceutical Industry by Product (2009)
Categories of Biosimilars Industry
Biosimilars Development Process
Difference between Small Molecule Generics and Biosimilars
Global Biosimilar Industry Revenue (2008-2014F)
Global Biosimilars Industry by Product (2009)
Global Industry Potential for Biosimilars in Different Categories (2009)
Major Blockbuster biologics whose patents will expire from 2012- 2019
Marketed Biosimilars by Product Group
Total Healthcare Expenditure Per Capita in Selected Developed Countries (2008)
Real Annual Growth in per Capita Health Spending (%): from 2000 to 2008
Potential Industry Potential for Biosimilars
Leading Players in Biosimilars industry and Products in Pipeline
Ageing Population Worldwide (age>65) from 2005 to 2015 F
Cost Comparison of Biosimilars and Innovator Biologics
Biosimilar Approval in EU
Indian Biosimilars Industry Revenue (2008-2012F)
India’s Biosimilar Industry Breakdown (2009)
Potential Global Industry for Biosimilars (2008-2015)
Number of Biologics Scheduled to Go-off Patent (2008-2015)
Annual Revenues of Teva Pharmaceuticals (2005-2009)
Annual Revenues of Biocon (FY06-FY10)
Annual Revenues of Hospira Inc. (2009)